Study of Aspirin in Patients With Vestibular Schwannoma

This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):


  • drug: Aspirin
  • drug: Placebo


Inclusion Criteria:

* Radiographic diagnosis of vestibular schwannoma (NF2-associated or sporadic).
* Age≥12 years.
* Ability to provide informed consent.Pediatric patients must provide assent in addition to their parents'/guardians' consent. Adult patients who cannot consent for themselves will not be eligible to participate in this study.
* Ability to swallow tablets.

Exclusion Criteria:

* Inability to perform volumetric measurements of vestibular schwannoma(s).
* Inability to tolerate MRI with contrast.
* Daily use of aspirin within the last two months. Occasional use of aspirin for pain relief is not exclusionary.
* Known allergy to aspirin.
* Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of aspirin.
* Pregnant or lactating women.
* Patients with serious medical illnesses (e.g. severe asthma) that in the option of the investigator could prevent participation in the trial.
* Active bleeding diathesis.
* Hydrocephalus from brainstem compression.
* Febrile illness or flu-like illness in children and adolescents less than 18 years of age.

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Homer Abaya
I'm interested